Category: Legislative

U.S. Senate appropriators say they’re happy with the federal government’s response to six drug manufacturers’ denials of 340B drug discounts involving contract pharmacy.

If Congress changes hands during next year’s mid-term elections, we can expect the 340B program to be back under the spotlight with a renewed effort to place significant restrictions on the program, 340B Report Publisher and CEO Ted Slafsky writes

Pharmaceutical industry vendor Kalderos has asked a federal court to vacate a federal health agency’s policy prohibiting drug manufacturers from conditioning 340B drug discounts on covered entities’ submission of drug claims data.

Montana’s at-large Republican U.S. congressman has introduced a bill to impose a host of new conditions on hospital participation in the drug discount program.

Half of the Congressional Black Caucus (CBC) has asked Centers for Medicare & Medicaid Services (CMS) Administrator Chiquita Brooks-LaSure to end the nearly 30% cut in Medicare Part B drug payments to 340B hospitals.

It appears increasingly likely that congressional Democrats will miss their self-appointed deadline to pass and sent to President Biden this week a $3.5 trillion economic and social welfare bill including major drug pricing reforms.

A Republican U.S. senator on an important health care spending committee wants Congress to pass a law preserving the Trump administration’s controversial requirement that community health centers pass along all their 340B savings on insulin and EpiPen-like devices to low-income,

Six national hospital groups late last week urged Democratic and Republican congressional leaders to exclude language “that would negatively impact 340B” from major drug pricing reforms that could be voted on this week.

U.S. Sen. Chuck Grassley (R-Iowa)—one of the most-engaged members of Congress on 340B matters—has announced he will seek an eighth Senate term in next year’s congressional elections.

U.S. Sen. Mike Braun (R-Ind.) introduced legislation last night to let the federal government audit 340B covered entities to determine how they use net income from drugs bought under the 340B program.